Catabasis Pharmaceuticals
Region | Nordamerika |
ISIN | US14875P2065 |
Sektor | Biotechnologie |
Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
Titel | Autor | Datum |
---|---|---|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor ungefähr 5 Jahren |
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | translation missing: de.datetime.time_ago_in_words.almost_x_years |
Titel | Datum |
---|---|
SBM Offshore finalizes asset swap with MISC Berhad | vor 10 Tagen |
SBM Offshore and MISC wrap up FPSO stake swap | vor 11 Tagen |
SBM Offshore N.V.: SBM Offshore completes the Share Purchase Agreements with MISC Berhad
Amsterdam, January 31, 2025 SBM Offshore confirms it has completed the transactions related to t... |
vor 11 Tagen |
MPA Singapore and MISC to support digital transformation in maritime industry | vor ungefähr 2 Monaten |
The Maritime and Port Authority of Singapore and MISC forge partnership | vor ungefähr 2 Monaten |
Diese Aktien könnten Dich auch interessieren | |
---|---|
Cannabis Wheaton Income (2 Artikel) | |
BYD Company (1 Artikel) | |
CBLT (1 Artikel) | |
Celgene (1 Artikel) | |
Alle anzeigen |